Literature DB >> 17680646

Receptor-mediated endocytosis of immune complexes in rat liver sinusoidal endothelial cells is mediated by FcgammaRIIb2.

Seyed Ali Mousavi1, Marita Sporstøl, Cathrine Fladeby, Rune Kjeken, Nicolas Barois, Trond Berg.   

Abstract

UNLABELLED: Liver sinusoidal endothelial cells (LSECs) display a number of receptors for efficient uptake of potentially injurious molecules. The receptors for the Fc portion of immunoglobulin G (IgG) antibodies (FcgammaRs) regulate a number of physiological and pathophysiological events. We used reverse transcription polymerase chain reaction (RT-PCR) and Western blotting to determine the expression of different types of FcgammaRs in LSECs. Biochemical approaches and immunofluorescence microscopy were used to characterize the FcgammaR-mediated endocytosis of immune complexes (ICs). FcgammaRIIb2 was identified as the main receptor for the efficient uptake of ICs in LSECs. The receptor was shown to use the clathrin pathway for IC uptake; however, the association with lipid rafts may slow the rate of its internalization. Moreover, despite trafficking through lysosomal integral membrane protein-II (LIMP-II)-containing compartments, the receptor was not degraded. Finally, it was shown that the receptor recycles to the cell surface both with and without IC.
CONCLUSION: FcgammaRIIb2 is the main receptor for endocytosis of ICs in rat LSECs. Internalized ICs are degraded with slow kinetics, and IC internalization is not linked to receptor downregulation. After internalization, the receptor recycles to the cell surface both with and without ICs. Thus, FcgammaRIIb2 in rat LSECs is used as both a recycling receptor and a receptor for efficient IC clearance.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17680646     DOI: 10.1002/hep.21748

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  42 in total

Review 1.  Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy.

Authors:  Narendra Chirmule; Vibha Jawa; Bernd Meibohm
Journal:  AAPS J       Date:  2012-03-10       Impact factor: 4.009

2.  Differential requirement of lipid rafts for FcγRIIA mediated effector activities.

Authors:  Joshua A Vieth; Moo-Kyung Kim; Xiao Qing Pan; Alan D Schreiber; Randall G Worth
Journal:  Cell Immunol       Date:  2010-08-01       Impact factor: 4.868

3.  Sinusoidal obstruction syndrome following CD33-targeted therapy in acute myeloid leukemia.

Authors:  Colin D Godwin; George B McDonald; Roland B Walter
Journal:  Blood       Date:  2017-02-02       Impact factor: 22.113

Review 4.  Liver Sinusoidal Endothelial Cell: An Update.

Authors:  Laurie D DeLeve; Ana C Maretti-Mira
Journal:  Semin Liver Dis       Date:  2017-12-22       Impact factor: 6.115

5.  FcγRIIb on liver sinusoidal endothelium clears small immune complexes.

Authors:  Latha P Ganesan; Jonghan Kim; Yun Wu; Sudhasri Mohanty; Gary S Phillips; Daniel J Birmingham; John M Robinson; Clark L Anderson
Journal:  J Immunol       Date:  2012-10-10       Impact factor: 5.422

6.  Divergent intracellular sorting of Fc{gamma}RIIA and Fc{gamma}RIIB2.

Authors:  Christine Y Zhang; James W Booth
Journal:  J Biol Chem       Date:  2010-08-24       Impact factor: 5.157

Review 7.  Three major uncertainties in the antibody therapy of cancer.

Authors:  George T Stevenson
Journal:  Haematologica       Date:  2014-10       Impact factor: 9.941

Review 8.  Liver sinusoidal endothelial cells in hepatic fibrosis.

Authors:  Laurie D DeLeve
Journal:  Hepatology       Date:  2015-03-23       Impact factor: 17.425

9.  Liver Complications Following Treatment of Hematologic Malignancy With Anti-CD22-Calicheamicin (Inotuzumab Ozogamicin).

Authors:  George B McDonald; James W Freston; James L Boyer; Laurie D DeLeve
Journal:  Hepatology       Date:  2019-01-18       Impact factor: 17.425

10.  IgG is transported across the mouse yolk sac independently of FcgammaRIIb.

Authors:  Sudhasri Mohanty; Jonghan Kim; Latha P Ganesan; Gary S Phillips; Keding Hua; David Jarjoura; William L Hayton; John M Robinson; Clark L Anderson
Journal:  J Reprod Immunol       Date:  2009-12-16       Impact factor: 4.054

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.